Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CDP323 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| CDP323 | DRUG | 50mg capsules, 100mg bid for 4 weeks |
| Placebo | DRUG | placebo capsules for 4 weeks |
Inclusion Criteria: * Female and male subjects aged 18-65 years * Relapsing form of MS with at least one clinical relapse in the 24 months before screening; * Screening EDSS score of 0-6.5; * Must be fully immunocompetent * Female subjects of childbearing potential must agree to practice contracept...
CDP323 is an investigational small molecule being developed for the treatment of relapsing multiple sclerosis. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied for its potential effects on this neurological condition.
CDP323 is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. The company is conducting clinical research on this investigational small molecule for relapsing multiple sclerosis.
CDP323 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. The drug is being studied for the treatment of relapsing multiple sclerosis, and its clinical development is still in the early stages.
CDP323 has been studied in one completed Phase 1 clinical trial, identified as NCT00726648, titled "CDP323 Biomarker Study." This trial enrolled 71 participants with relapsing multiple sclerosis in the United Kingdom. The study was randomized, double-blind, and placebo-controlled, and it has been completed.
CDP323 is a small molecule being investigated for relapsing multiple sclerosis. The specific molecular target of CDP323 has not been disclosed in the available information, so its mechanism of action is not publicly detailed.